Translate this page into:
Original Article
doi:
10.4103/sajc.sajc_126_18
Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
1
Department of Medical Oncology, Fortis Hospital, Kolkata, West Bengal
2
Department of Medical Oncology, Max Hospital, New Delhi
3
Department of Medical Oncology, Jaypee Hospital, Noida, Uttar Pradesh
4
Department of Medical Oncology, Sarvodaya Hospital, Faridabad, Haryana
5
Department of Oncology, Hakim Sanaullah Cancer Center, Sopore, Jammu and Kashmir
6
Department of Medical Oncology, RGCI, New Delhi
7
Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi
8
Department of Oncology, Shalby Cancer and Research Institute, Mumbai, Maharashtra
*Corresponding author: Dr. G. S. Bhattacharyya. docgsbhattacharyya@gmail.com
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Abstract
This manuscript provides a practical and easy to use consensus recommendation to community oncologists on how to use neoadjuvant chemotherapy in triple negative breast cancer patients.
Keywords
References
- von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796-804.
- Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 2014;384:164-72.
- Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007;CD005002.
- Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011;17:1082-9.
- Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015;33:304-11.
- NCCN Guidelines for Detection. Prevention, and Risk Reduction Genetic/Familial High-Risk Assessment: Breast and Ovarian, v 2; 2016. Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf. [Last accessed on 2017 Oct 17].
- Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015;33:13-21.
- von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol 2014;15:747-56.
- Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: A single-institution experience. J Clin Oncol 2011;29:3739-46.
- Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010;28:375-9.
- Tutt A, Ellis P, Kilbum L. TNT: A randomized phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced triple-negative or BRCA1/2 breast cancer. San Antonio Breast Cancer Symposium. 2014. p. S3-01.
- Enokido K, Watanabe C, Nakamura S, Ogiya A, Osako T, Akiyama F, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with an initial diagnosis of cytology-proven lymph node-positive breast cancer. Clin Breast Cancer 2016;16:299-304.
- Mocellin S, Goldin E, Marchet A, Nitti D. Sentinel node biopsy performance after neoadjuvant chemotherapy in locally advanced breast cancer: A systematic review and meta-analysis. Int J Cancer 2016;138:472-80.